
Tibet Weixinkang Medicine Co., Ltd.
SSE:603676.SS
11.51 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,300.235 | 1,322.649 | 1,398.543 | 1,033.623 | 715.667 | 740.963 | 746.325 | 420.382 | 426.361 | 440.234 | 390.795 | 342.298 |
Cost of Revenue
| 594.936 | 651.244 | 662.875 | 500.401 | 384.116 | 393.621 | 400.144 | 177.735 | 160.987 | 161.212 | 125.174 | 115.628 |
Gross Profit
| 705.299 | 671.405 | 735.668 | 533.221 | 331.551 | 347.342 | 346.181 | 242.647 | 265.374 | 279.022 | 265.621 | 226.67 |
Gross Profit Ratio
| 0.542 | 0.508 | 0.526 | 0.516 | 0.463 | 0.469 | 0.464 | 0.577 | 0.622 | 0.634 | 0.68 | 0.662 |
Reseach & Development Expenses
| 116.01 | 112.82 | 72.453 | 38.019 | 23.195 | 29.138 | 24.443 | 25.015 | 27.178 | 30.921 | 23.243 | 0 |
General & Administrative Expenses
| 33.478 | 42.26 | 74.145 | 41.055 | 13.481 | 11.293 | 13.571 | 12.735 | 17.536 | 20.417 | 18.896 | 68.096 |
Selling & Marketing Expenses
| 177.862 | 255.417 | 312.189 | 275.506 | 191.258 | 202.151 | 199.698 | 79.698 | 70.501 | 72.21 | 65.239 | 53.741 |
SG&A
| 211.34 | 297.677 | 386.333 | 316.561 | 204.739 | 213.444 | 213.269 | 92.433 | 88.036 | 92.627 | 84.135 | 121.837 |
Other Expenses
| 97.092 | -18.095 | 109.696 | 81.256 | 58.293 | 60.009 | 1.099 | 26.737 | 14.078 | 6.094 | 10.697 | 11.352 |
Operating Expenses
| 424.443 | 497.138 | 568.483 | 435.836 | 286.227 | 302.591 | 290.416 | 157.876 | 153.91 | 158.727 | 140.109 | 126.334 |
Operating Income
| 280.856 | 174.963 | 162.602 | 102.285 | 44.668 | 55.222 | 76.644 | 88.67 | 113.319 | 120.774 | 127.227 | 100.828 |
Operating Income Ratio
| 0.216 | 0.132 | 0.116 | 0.099 | 0.062 | 0.075 | 0.103 | 0.211 | 0.266 | 0.274 | 0.326 | 0.295 |
Total Other Income Expenses Net
| -4.253 | 40.875 | 19.753 | 11.943 | 10.336 | 10.711 | 1.099 | 26.737 | 13.567 | 5.381 | 9.858 | 8.095 |
Income Before Tax
| 276.603 | 215.838 | 182.355 | 114.228 | 69.62 | 65.933 | 77.743 | 115.408 | 126.886 | 126.155 | 137.085 | 108.923 |
Income Before Tax Ratio
| 0.213 | 0.163 | 0.13 | 0.111 | 0.097 | 0.089 | 0.104 | 0.275 | 0.298 | 0.287 | 0.351 | 0.318 |
Income Tax Expense
| 30.434 | 1.821 | 5.397 | 18.317 | 11.195 | 10.255 | 4.307 | 13.82 | 11.971 | 13.129 | 20.884 | 21.18 |
Net Income
| 246.169 | 214.017 | 176.958 | 95.911 | 58.425 | 55.678 | 73.436 | 101.587 | 114.916 | 112.935 | 106.736 | 82.95 |
Net Income Ratio
| 0.189 | 0.162 | 0.127 | 0.093 | 0.082 | 0.075 | 0.098 | 0.242 | 0.27 | 0.257 | 0.273 | 0.242 |
EPS
| 0.57 | 0.5 | 0.41 | 0.23 | 0.14 | 0.13 | 0.17 | 0.26 | 0.32 | 0.62 | 50.83 | 0.46 |
EPS Diluted
| 0.57 | 0.5 | 0.41 | 0.23 | 0.14 | 0.13 | 0.17 | 0.26 | 0.32 | 0.62 | 50.83 | 0.46 |
EBITDA
| 329.719 | 266.606 | 225.689 | 152.438 | 68.518 | 94.168 | 100.902 | 134.669 | 131.526 | 132.421 | 136.442 | 107.309 |
EBITDA Ratio
| 0.254 | 0.202 | 0.161 | 0.147 | 0.096 | 0.127 | 0.135 | 0.32 | 0.308 | 0.301 | 0.349 | 0.313 |